ARMO Rides Immuno-Oncology Wave With $50m For Its PD-1 Booster
This article was originally published in Scrip
Investors who backed a $50m Series C venture capital round for ARMO BioSciences are betting that the Redwood City, California-based company will be part of a second immuno-oncology wave with pegylated interleukins that are designed to boost the field's first wave of new therapies.
You may also be interested in...
The first three months of the year should bring late-stage clinical trial read-outs for a range of novel products including Johnson & Johnson's esketamine, Esperion's bempedoic acid, ImmuPharma's Lupuzor and VBL's gene therapy for brain cancer.
Seven biopharma IPOs launched in the US in January with an average return of 52.8%. The most recent was Sol-Gel's on Jan. 31, but the largest was a $128m offering by ARMO. Solid had the most controversial IPO, but it still gave investors a 70.7% return, contributing to the question: Is biotech in a bubble?
Lilly will save $500m annually starting in 2018 after $1.2bn in layoff-related costs to reinvest in new products. Also, Cytori halves its headcount; VC OrbiMed closed a $551m Asia fund; and Insmed capitalizes on positive data.